9 Meters Biopharma, Inc. (NMTR)
Chart Events
Performance Outlook
| Previous Close | 1.6650 |
| Open | 1.6959 |
| Bid | 1.6400 x 4000 |
| Ask | 1.6600 x 3200 |
| Day's Range | 1.5901 - 1.8200 |
| 52 Week Range | 0.3700 - 2.2600 |
| Volume | 4,628,796 |
| Avg. Volume | 11,197,767 |
| Market Cap | 337.647M |
| Beta (5Y Monthly) | -0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 12, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
Fair Value
Related Research
- Analyst Report: Exact Sciences Corporation
- Market Digest: AVY, BSX, EL, EA, ETN, TT, ITW, MAN, NFG, VSH, APO
- ACCESSWIRE
9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference
RALEIGH, NC / ACCESSWIRE / February 10, 2021 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that its Chief Executive Officer, John Temperato, will present a corporate overview and participate in one-on-one investor meetings at the BIO CEO & Investor Conference.
- Zacks
9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming?
9 Meters Biopharma (NMTR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
- ACCESSWIRE
9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series
RALEIGH, NC / ACCESSWIRE / February 3, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced its Executive Management team will participate in the "CEO Strategic Vision" Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD of Truist Securities on Wednesday, February 10, 2021.
